Astd.Bo
ASTD.BO is a pharmaceutical company that develops and commercializes drugs, primarily generating revenue through the sale of prescription medications.
Business. ASTD.BO is a pharmaceutical company that develops and commercializes drugs, primarily generating revenue through the sale of prescription medications.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ASTD.BO is a pharmaceutical company that develops and commercializes drugs, primarily generating revenue through the sale of prescription medications.
The company's capital structure is characterized by a high debt-to-equity ratio of 2.9, indicating a significant reliance on debt financing relative to equity. Liquidity is assessed as medium, with a current ratio of 1.13, suggesting the company has just enough current assets to cover its current liabilities. However, the company's cash and equivalents amount to only INR 848,000, which is far below the long-term debt of INR 533,370,000, resulting in a net cash position that is negative after subtracting total debt.
In terms of profitability, ASTD.BO reports a return on equity (ROE) of 58.12% and a return on assets (ROA) of 10.35%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures suggest the company is performing well compared to typical industry benchmarks, although specific cohort medians for the Pharmaceuticals industry are not provided in the available data.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is disclosed in the available data. There is no geographic breakdown provided, so it is unclear whether the company's revenue is diversified across regions or concentrated in a specific market.
Looking ahead, the company's growth trajectory is not explicitly outlined in the available data. However, the operating cash flow of INR 184,990,000 and free cash flow of INR 44,909,000 suggest the company is generating positive cash from operations, which could support future growth initiatives. The capital expenditure of INR -107,916,000 indicates that the company is not currently investing heavily in new assets, which may limit its ability to scale operations or develop new products.
The company's risk profile includes a medium liquidity risk, primarily due to its limited cash reserves relative to its debt obligations. The dilution risk is assessed as low, with no near-term pressure expected, as the number of shares outstanding has not changed between basic and diluted shares. No recent events, such as filings or transcripts, are provided in the available data to further inform the company's risk outlook.
- ASTD.BO has a strong return on equity (58.12%) and return on assets (10.35%), indicating efficient use of capital and assets.
- The company's liquidity is medium, with a current ratio of 1.13 and limited cash reserves relative to its debt.
- ASTD.BO is highly leveraged, with a debt-to-equity ratio of 2.9, suggesting a significant reliance on debt financing.
- The company is generating positive operating and free cash flows, which could support future growth.
- There is no indication of near-term dilution risk, as the number of shares outstanding remains unchanged.
- The company's geographic and segmental revenue exposure is not disclosed, limiting visibility into diversification.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ASTD.BO Market data — financials · 2026-05-27